文献速递冠心病

Ponatinib而非Asciminib通过激活血小板、白细胞及内皮细胞TNF信号诱导动脉粥样硬化斑块炎症、心肌梗死和卒中

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.
PubMed 文献 · Circulation · 2025-08-05

该研究在小鼠模型中比较了伊马替尼、Ponatinib和Asciminib的心血管效应,发现Ponatinib显著加速SR-BI-mut/LDLR-KO小鼠死于心肌梗死和卒中,并激活内皮细胞、血小板和白细胞,而Asciminib未诱导这些毒性。抑制TNFR信号可阻止Ponatinib诱导的斑块炎症和心血管事件。

要点

  • Ponatinib加速小鼠MI和卒中死亡,Asciminib无此效应。
  • Ponatinib通过TNFR2上调内皮黏附分子,促进血栓炎症。
  • 抑制TNFR可预防Ponatinib诱导的斑块炎症和心血管事件。

核心结论

  • Ponatinib激活内皮细胞、血小板和白细胞,驱动斑块炎症及MI和卒中死亡,而Asciminib未诱导这些效应。
  • 抑制TNFR介导的内皮活化足以预防Ponatinib诱导的主要不良心血管事件。

研究设计与样本

  • 使用SR-BI-mut/LDLR-KO小鼠评估自发性MI和卒中风险,比较临床相关血浆浓度的伊马替尼、Ponatinib和Asciminib与溶媒。
  • 在C57BL/6J小鼠中通过活体显微镜和流式细胞术评估白细胞运输和血栓炎症。
  • 在ApoE-KO小鼠中通过流式细胞术和组织学评估斑块表型。
  • 体外使用人脐静脉内皮细胞和人冠状动脉内皮细胞,通过流式细胞术、PCR和免疫印迹检测。
  • 通过药理学抑制和小干扰RNA敲低评估TNF信号的作用。

主要发现

  • 在SR-BI-mut/LDLR-KO小鼠中,Ponatinib较溶媒、伊马替尼和Asciminib显著加速死于MI和卒中。
  • 在人内皮细胞中,仅Ponatinib增加TNF受体和黏附分子(P-selectin、ICAM1、VCAM1)表达。
  • Ponatinib快速诱导人脐静脉内皮细胞中TNFR2膜运输和TNF信号。
  • TNFR抑制或TNFR2敲低阻止Ponatinib诱导的内皮黏附分子表达。
  • 在ApoE-KO小鼠中,Ponatinib增加斑块坏死核心和炎症,Asciminib未诱导这些毒性。

临床怎么用

  • 对于伊马替尼耐药患者,Asciminib可能比Ponatinib具有更佳的心血管安全性。
  • 抑制TNFR信号可能预防Ponatinib诱导的主要不良心血管事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Imatinib, the first Abl-tyrosine kinase inhibitor (TKI), improved leukemia outcomes without cardiovascular side effects. Newer agents, including ponatinib, addressed imatinib resistance, improving cancer remission, but substantially increased arterial thrombotic events, including myocardial infarction (MI) and stroke. The mechanism behind ponatinib-induced thrombosis and the cardiovascular effect of asciminib, a newly approved Abl-TKI, remain unknown. METHODS: The effect of clinically relevant plasma concentrations of imatinib, ponatinib, and asciminib were compared with vehicle in vivo using SR-BI-mut/LDLR-knockout (KO) mice to assess spontaneous MI and stroke risk. The mechanism was interrogated in C57BL/6J mice, assessing leukocyte trafficking and thromboinflammation by intravital microscopy and flow cytometry, respectively, and in ApoE-KO mice, assessing plaque phenotype by flow cytometry and histology. In vitro effects on human umbilical vein endothelial cells (ECs) and human coronary artery ECs were determined by flow cytometry, PCR, and immunoblotting. The role of TNF (tumor necrosis factor) signaling was evaluated by pharmacological inhibition and small interfering RNA knockdown. RESULTS: In SR-BI-mut/LDLR-KO mice, ponatinib significantly accelerated death from MI and stroke compared with vehicle, imatinib, and asciminib. In human ECs, only ponatinib increased expression of TNF receptors (TNFRs) and adhesion molecules (P-selectin, ICAM1 [intercellular adhesion molecule 1], and VCAM1 [vascular cell adhesion molecule 1]). Ponatinib rapidly induced TNFR2 membrane trafficking and TNF signaling in human umbilical vein ECs. TNFR inhibition or TNFR2 knockdown prevented ponatinib induction of EC adhesion molecules. In vivo, ponatinib increased mesenteric vessel adhesion molecules, leukocyte rolling and adhesion to vessels, leukocyte and platelet activation, and platelet-leukocyte aggregates. In ApoE-KO mice, ponatinib increased plaque necrotic core and inflammation, consistent with a rupture-prone phenotype. Asciminib-treated mice developed none of these in vitro or in vivo toxicities. In C57BL/6J mice, TNFR inhibition blocked ponatinib-induced mesenteric adhesion molecule expression and leukocyte trafficking, but not platelet-leukocyte aggregation. TNFR blockade prevented ponatinib-induced plaque inflammation in ApoE-KO mice and MI and stroke in SR-BI-mut/LDLR-KO mice. CONCLUSIONS: Ponatinib, a potent anticancer therapy, activates ECs, platelets, and leukocytes, driving plaque inflammation and death from MI and stroke in mice, mirroring clinical cardiotoxicities in patients with cancer. Asciminib did not induce these effects, suggesting it might be a safer option for imatinib-resistant patients with cancer. Inhibition of TNFR-mediated endothelial activation is sufficient to prevent ponatinib-induced major adverse cardiovascular events.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Stepanian, Travers, Tesfu, et al. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. Circulation. 2025. PMID: 40762051. doi:10.1161/CIRCULATIONAHA.125.073610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。